Submandibular gland transfer reduced salivary-gland dose by 12 Gy during proton therapy
Surgical transfer reduced contralateral submandibular mean dose by approximately 12 Gy during bilateral IMPT without compromising target coverage.
Tag
oropharynx
BARitOne will escalate oropharyngeal dose only for MRI-defined non-responders
BARitOne uses on-treatment diffusion MRI to increase gross tumour dose from 65 to 73 Gy only in predicted non-responders.
FDG-PET-guided dose escalation did not improve control in advanced oropharyngeal and laryngopharyngeal cancers
Escalating metabolically active disease to 73.5 Gy did not improve locoregional control, disease-free survival, or overall survival versus 66 Gy.
Planning computed tomography radiomics predicted recurrence in human papillomavirus-positive oropharyngeal cancer
A multi-regional clinical-radiomics model reached an external-test area under the curve of 0.908 for 5-year recurrence prediction.
No isolated failures in omitted nodal regions with reduced elective irradiation for early oropharyngeal cancer
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
Mid-treatment tumour shrinkage predicted survival in oropharyngeal cancer
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.
Dose de-escalation improved patient-reported outcomes in early p16-positive oropharyngeal cancer
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
Concurrent chemotherapy improved progression-free but not overall survival in low-volume head and neck cancer
Concurrent chemotherapy improved progression-free survival without a significant overall survival benefit in early primary tumors with low-volume nodal disease.